Abstract
Deficiency of Interleukin-1 receptor antagonist (DIRA) is a rare autosomal recessive autoinflammatory disease caused by loss-of-function mutations in the IL1RN gene. Currently, limited information exists on all of its known genetic variants, particularly their impacts on the function and stability of resulting IL1RN mRNA and IL-1Ra proteins. To address this current gap, we analyzed 15 unique mRNA transcripts and 10 subsequent IL-1Ra. Using the biopython computational tool, we first predicted changes in molecular properties of IL-1Ra based on amino acid compositions and prior empirical models. An RNA secondary structure prediction was then conducted to identify potential local and global changes in the minimum free energy structures with RNAfold. We then performed a structural analysis of the resulting IL-1Ra and IL-1R1 complexes. After predicting the mRNA secondary structures, we report alterations in stability, base pairing, and structure. From the structural analysis of IL-1Ra, we provide insights into changes in structure (β-sheets, α-helices) and stability of the overall complex. Lastly, we evaluate the pathogenic mechanisms proposed from prior studies and discuss them in the context of this work. Overall, although further in vivo experimental studies are still required to investigate the mRNA structure and IL-1Ra expression, this work provides valuable preliminary insights into the pathogenic impacts of the variants on the IL1RN mRNA and IL-1Ra protein.
Highlights
This is the first study broadly investigating the known genetic variants of DIRA disease.
Structural analysis revealed that 80% of variants retained 3 or less β-sheets and 60% lacked any α-helices.
All mutations appear to have a destabilizing effect on the conformation of IL-1Ra from stability data.
Large deletion variants had an altered global mRNA structure, while nonsense and frameshift variants appear with more subtle local changes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study received no funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All supporting data and analysis is available in Supplementary Materials 1-3 and data repository website (https://diradisease.github.io). Any further inquiries can be sent to the corresponding author.
Abbreviations
- IL-1Ra
- Interleukin-1 Receptor Antagonist
- DIRA
- Deficiency of Interleukin-1 Receptor Antagonist
- NCBI
- National Center for Biotechnology Information
- PDB
- Protein Data Bank
- MSA
- Multiple Sequence Alignment
- WT
- Wild Type
- MFE
- Minimum Free Energy
